New pill targets Hard-to-Treat cancers with KRAS mutations
NCT ID NCT07542704
First seen Apr 26, 2026 · Last updated Jun 23, 2026 · Updated 11 times
Summary
This early-stage trial tests an oral drug called KQB368 in 48 adults with advanced solid tumors (like lung, colorectal, or uterine cancer) that have specific KRAS gene mutations (G12C or G12S). The main goals are to find a safe dose and see if the drug can shrink tumors. Participants take the drug daily in 21-day cycles and are monitored closely for side effects and how the drug behaves in the body.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
KQB368 (oral drug)
What this could lead to
If successful, this could point toward a new treatment option for certain advanced cancers with KRAS mutations.
What could go wrong
This is a very early Phase 1 trial with only 48 participants, so safety and effectiveness are not yet known. The drug may not shrink tumors or could cause side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.